| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/12/2001 | CA2331059A1 Method of reducing morbidity and the risk of mortality |
| 07/12/2001 | CA2330465A1 Process for increasing egg production and strenghtening poultry egg shell |
| 07/11/2001 | EP1114862A2 Use of polyeptides or their encoding nucleic acids for the diagnosis or treatment of skin diseases and their use in indentifying pharmacologically acitve substances |
| 07/11/2001 | EP1114826A2 Novel antibacterial and prokinetic macrolides |
| 07/11/2001 | EP1114823A2 Substituted benzylamino nitrogen containing non-aromatic heterocycles |
| 07/11/2001 | EP1114822A2 Indoles and tetrahydroisoquinolines containing alpha-keto oxadiazoles as serine protease inhibitors |
| 07/11/2001 | EP1114821A1 Benzopyrans and their use as therapeutic agents |
| 07/11/2001 | EP1114817A1 Substituted benzylamino piperidine compounds |
| 07/11/2001 | EP1114646A2 System and method for providing a sterile medical solution containing glucose or glucose-like compounds |
| 07/11/2001 | EP1114645A2 System and method for providing a sterile medical solution containing glucose or glucose-like compounds |
| 07/11/2001 | EP1114642A1 Drugs for periodontal diseases |
| 07/11/2001 | EP1114641A2 Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid |
| 07/11/2001 | EP1114639A2 Use of a mixture of a co-surfactant and a surfactant (e.g. SLES) for the preparation of particularly skin compatible cosmetic or dermatologic cleansing compositions |
| 07/11/2001 | EP1114166A1 Method for down-regulating osteoprotegerin ligand activity |
| 07/11/2001 | EP1114160A1 Moraxella catarrhalis basb034 polypeptides and uses thereof |
| 07/11/2001 | EP1114157A2 Regulatory protein from human keratinocytes |
| 07/11/2001 | EP1114145A1 Topa |
| 07/11/2001 | EP1114144A1 Treatment of oncologic tumors with an injectable formulation of a golgi apparatus disturbing agent |
| 07/11/2001 | EP1114053A1 Pyrrolopyrimidines as protein kinase inhibitors |
| 07/11/2001 | EP1114052A1 4-aminopyrrolopyrimidines as kinase inhibitors |
| 07/11/2001 | EP1114051A1 INHIBITORS OF p38 |
| 07/11/2001 | EP1114049A1 3-bicycloindole compounds as 5-ht1d receptor ligands |
| 07/11/2001 | EP1114048A1 Carboline derivatives as cgmp phosphodiesterase inhibitors |
| 07/11/2001 | EP1114046A1 Interleukin-5 inhibiting 6-azauracil derivatives |
| 07/11/2001 | EP1114040A1 PROCESS FOR OBTAINING HMG-CoA REDUCTASE INHIBITORS OF HIGH PURITY |
| 07/11/2001 | EP1114039A1 INHIBITORS OF p38 |
| 07/11/2001 | EP1114037A1 Benzoxazine and benzothiazine derivatives and their use in medicines |
| 07/11/2001 | EP1114035A1 Quinazoline derivatives and pharmaceutical applications thereof |
| 07/11/2001 | EP1114033A1 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines as cetp inhibitors |
| 07/11/2001 | EP1114032A1 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors |
| 07/11/2001 | EP1114031A1 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors |
| 07/11/2001 | EP1114029A1 Novel compounds |
| 07/11/2001 | EP1114028A1 Aza-bicycles which modulate the inhibition of cell adhesion |
| 07/11/2001 | EP1114024A1 Urokinase inhibitors |
| 07/11/2001 | EP1113820A1 Expandible microparticle intracellular delivery system |
| 07/11/2001 | EP1113819A2 Antibody directed enzyme prodrug therapy (adept) with glucuronidase |
| 07/11/2001 | EP1113818A1 METHODS OF TREATING IgE-ASSOCIATED DISORDERS AND COMPOSITIONS FOR USE THEREIN |
| 07/11/2001 | EP1113806A1 Anionic or cationic dendrimer antimicrobial or antiparasitic compositions |
| 07/11/2001 | EP1113805A1 Inhibition of toxic materials or substances using dendrimers |
| 07/11/2001 | EP1113803A1 Antiviral combinations comprising lamivudine and abacavir |
| 07/11/2001 | EP1113802A2 Antiviral combinations of lamivudine and adefovir |
| 07/11/2001 | EP1113801A1 METHOD FOR TREATING ATHEROSCLEROSIS EMPLOYING AN aP2 INHIBITOR AND COMBINATION |
| 07/11/2001 | EP1113800A1 Combinations of tetracyclic cyclic gmp-specific phosphodiesterase inhibitors with further therapeutic agents |
| 07/11/2001 | EP1113799A1 Protein formulations |
| 07/11/2001 | EP1113798A1 Topical formulation of alkyl-, phenyl-pyridone |
| 07/11/2001 | EP1113797A1 Treatment of persistent pain |
| 07/11/2001 | EP1113796A1 FUSED PYRIDINE INHIBITORS OF cGMP PHOSPHODIESTERASE |
| 07/11/2001 | EP1113795A2 Tryptophanyl ester and their n-acyl derivatives for the prevention and treatment of diseases caused or exacerbated by oxidation processes |
| 07/11/2001 | EP1113794A2 Methods of treating viral disease |
| 07/11/2001 | EP1113793A1 A new composition |
| 07/11/2001 | EP1113792A1 A new composition |
| 07/11/2001 | EP1113791A2 Bioflavonoid as blood glucose level lowering agent |
| 07/11/2001 | EP1113790A1 Composition containing cinnamic acid derivatives for preventing or treating elevated blood lipid level-related diseases |
| 07/11/2001 | EP1113789A1 Method and composition for treatment of inflammatory bowel disease |
| 07/11/2001 | EP1113787A1 Multiple unit controlled food effect-independent release pharmaceutical preparations and method for preparing the same |
| 07/11/2001 | EP1113786A1 New pharmaceutical formulation |
| 07/11/2001 | EP1113785A2 Preparation of aqueous clear solution dosage forms with bile acids |
| 07/11/2001 | EP1113726A1 Composition containing neohesperidin dihydrochalcone for preventing or treating elevated blood lipid and glucose level-related diseases |
| 07/11/2001 | EP1113724A1 Composition containing natural phenolic compounds for preventing or treating elevated blood lipid level-related diseases |
| 07/11/2001 | EP1019042A4 Anti-first-pass effect compounds |
| 07/11/2001 | EP1015452A4 Optionally protected 3-hydroxymethyl carbapenems and synthesis |
| 07/11/2001 | EP0969865A4 Mhc class ii antigen-presenting systems and methods for activating cd4?+ t cells |
| 07/11/2001 | EP0927037B1 Chlorofluorocarbon-free mometasone furoate aerosol formulations |
| 07/11/2001 | EP0912509B1 Distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents |
| 07/11/2001 | EP0885220B1 Tropane-derivatives, their preparation and use |
| 07/11/2001 | EP0876371B1 Reverse-turn mimetics and methods relating thereto |
| 07/11/2001 | EP0876350B1 Pyrazole derivatives, method for preparing same, and pharmaceutical compositions containing said derivatives |
| 07/11/2001 | EP0865422B1 Use of aminoalcoholderivatives as drugs, derivatives and process for their preparation |
| 07/11/2001 | EP0858328A4 Stable compositions containing n-propargyl-1-aminoindan |
| 07/11/2001 | EP0851734B1 Capsules containing freeze-dried powdered green tea leaves |
| 07/11/2001 | EP0823896B1 Substituted oximes, hydrazones and olefins as neurokinin antagonists |
| 07/11/2001 | EP0801651B1 Hydroxymethylimidazodiazepines and their esters |
| 07/11/2001 | EP0799615B1 Liposome eye drops |
| 07/11/2001 | EP0794785B1 Growth factor expression in human pregnant cervix |
| 07/11/2001 | EP0771195B1 Method of inhibiting nitric oxide formation |
| 07/11/2001 | EP0765323B1 4-(6-fluoro-1,2-benzisoxazolyl)-1-piperidinyl-propoxy-chromen-4-one derivatives, their preparation and their use in the treatment of psychosis, schizophrenia and anxiety |
| 07/11/2001 | EP0758231B1 Taxane class derivative based pharmaceutical compositions |
| 07/11/2001 | EP0752847B1 Ophthalmic composition with decreased viscosity |
| 07/11/2001 | EP0735876B1 Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin |
| 07/11/2001 | EP0735819B1 Cryptophycins |
| 07/11/2001 | EP0731808B1 Nucleosides and oligonucleotides containing boron clusters |
| 07/11/2001 | EP0725779B1 Novel (r)-5-carbamoyl-8-fluoro-3-n,n-disubstituted-amino-3,4-dihydro-2h-1-benzopyranes |
| 07/11/2001 | EP0683783B1 Rapamycin derivative process for its preparation and its use |
| 07/11/2001 | EP0679398B1 Immunopotentiating and infection protective agent and production thereof |
| 07/11/2001 | EP0660837B1 Penem derivatives, their preparation and pharmaceutical compositions containing them |
| 07/11/2001 | EP0659080B1 Method for the treatment of hair loss |
| 07/11/2001 | EP0658112B1 A conjugate comprising a straight-chained polymer having bound sulphated glucosaminoglucans such as heparin, its preparation, use and a corresponding substrate |
| 07/11/2001 | CN1303535A Method of suppressing reference oscillator harmonic interference and related receivers |
| 07/11/2001 | CN1303443A Compounds having glucuronic acid derivatives and glucosamine derivatives in structure, process for producing same and utilization thereof |
| 07/11/2001 | CN1303436A Compositions and methods for sensitizing and inhibiting growth of human tumor cells |
| 07/11/2001 | CN1303435A TAO protein kinases and methods of use therefor |
| 07/11/2001 | CN1303391A 17 Beta-amino and hydroxylamino-11 beta-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
| 07/11/2001 | CN1303390A Novel crystalline forms for antiviral benzimidazole compound |
| 07/11/2001 | CN1303389A 3',3'-N-substituted macrolide LHRH antagonists |
| 07/11/2001 | CN1303388A Platinum complex, its preparation and therapeutic application |
| 07/11/2001 | CN1303387A Platinum complex, its preparation and therapeutic application |
| 07/11/2001 | CN1303384A Pyrrolo [1,2-a] pyrazine sPLA2 inhibitor |
| 07/11/2001 | CN1303381A Dipeptidyl peptidase IV effectors |
| 07/11/2001 | CN1303380A Isothizole derivatives useful anticancer agents |
| 07/11/2001 | CN1303379A 2-Aminopyridines containing fused ring substituents as nitric oxide synthase inhibitors |